ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $5.36M fell 32.4% year over year, behind the -23.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.3% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -8.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.36M-0.3% QoQ
- Last fiscal yearDec 2025
- $23.85M-8.6% YoY
- LTMMar 2026
- $21.28M-23.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -32.4% | -100.0% | -67.6 pp |
| 1 year | -8.6% | -100.0% | -91.4 pp |
| 3-year CAGR | -6.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 23.85M USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- +0.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.85M | -8.6% |
| FY2024 | 2024-12-31 | 26.09M | -8.4% |
| FY2023 | 2023-12-31 | 28.48M | -1.9% |
| FY2022 | 2022-12-31 | 29.04M | +24.2% |
| FY2021 | 2021-12-31 | 23.39M | — |
Selling, General & Admin vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's LTM Mar 2026 selling, general & admin of $21.28M is the lowest of the 8 companies compared; the peer median is $37.85M.
- Its year-over-year change of -23.4% is the lowest of 8, against a peer median of +0.6%.
- Over three fiscal years its annual growth of -6.3% compares with a peer median of +10.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $76.67M | +0.6% | +17.4% | 120.8% | |
| LTM Jun 2026 | $75.77M | +15.3% | +15.9% | 72.2% | |
| LTM Mar 2026 | $71.21M | +35.2% | +19.9% | 222.0% | |
| LTM Mar 2026 | $37.85M | +8.5% | +10.0% | 88.1% | |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $25.06M | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $23.71M | -4.5% | +3.4% | 10537.3% | |
| LTM Mar 2026 | $21.28M | -23.4% | -6.3% | — | |
| Peer median (excluding ALXO) | $37.85M | +0.6% | +10.0% | 120.8% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 60.17M | 98.4M | 141.8M | 116.37M | 77M |
| Selling, General & Admin | 23.39M | 29.04M | 28.48M | 26.09M | 23.85M |
| Operating Expenses | 83.56M | 127.44M | 170.28M | 142.47M | 104.02M |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| EBITDA | (83.42M) | (122.84M) | (158.4M) | (132.25M) | (99.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.56M) | (127.44M) | (170.28M) | (142.47M) | (104.02M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 91 | 4.28M | 10.65M | 9.37M | 3.96M |
| Interest Expense | 13K | 238K | 1.57M | 1.73M | 1.6M |
| Other Income / Expenses | 71K | 4.02M | 9.47M | 7.62M | 2.33M |
| Income Before Tax | (83.48M) | (123.42M) | (160.81M) | (134.85M) | (101.7M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | 64K | 0 | 0 | 0 |
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| EPS (Diluted) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| Weighted Avg Shares | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
| Weighted Avg Shares (Diluted) | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.